Five Prime Therapeutics, Inc. (FPRX) financial statements (2021 and earlier)

Company profile

Business Address 111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15627029342251714976
Cash and cash equivalents5644608150158
Short-term investments10122623341436713468
Receivables45134400
Other undisclosed current assets613514722
Total current assets:16728931144052815178
Noncurrent Assets
Operating lease, right-of-use asset31
Property, plant and equipment2329316544
Restricted cash and investments  22   
Deferred costs    222
Other noncurrent assets2310010
Other undisclosed noncurrent assets22  13(2)(2)
Total noncurrent assets:57333382044
TOTAL ASSETS:22432234444854815682
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities182537246173
Accounts payable1220210
Accrued liabilities1015281562 
Employee-related liabilities7778753
Taxes payable    46  
Deferred revenue1
Debt4      
Deferred rent credit 1
Deferred revenue and credits141518138
Contract with customer, liability1
Other undisclosed current liabilities      2
Total current liabilities:23275139792014
Noncurrent Liabilities
Long-term debt and lease obligation46      
Operating lease, liability46
Liabilities, other than long-term debt5292818325110
Deferred revenue and credits281832509
Deferred revenue5
Contract with customer, liability10
Deferred rent credit 18
Other liabilities   0001
Total noncurrent liabilities:51292818325110
Total liabilities:745679571127024
Stockholders' equity
Stockholders' equity attributable to parent1502652653924338558
Common stock0000000
Additional paid in capital582560421397373274210
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)00
Retained earnings (accumulated deficit)(432)(295)(156)(5)61(189)(152)
Total stockholders' equity:1502652653924338558
Other undisclosed liabilities and equity    3  
TOTAL LIABILITIES AND EQUITY:22432234444854815682

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net4031380  
Gross profit:15504031380  
Operating expenses(157)(196)(191)(130)(93)(57)(43)
Other undisclosed operating income     1914
Operating income (loss):(142)(146)(151)(99)287(38)(29)
Nonoperating income5632001
Investment income, nonoperating5632000
Other nonoperating income (expense)  (0) (0)(0)0
Income (loss) from continuing operations before income taxes:(137)(140)(149)(97)287(37)(29)
Income tax expense (benefit)  (2)31(38)  
Net income (loss) available to common stockholders, diluted:(137)(140)(150)(66)250(37)(29)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(137)(140)(150)(66)250(37)(29)
Other comprehensive income (loss)00(0)0(0)(0)(0)
Comprehensive income (loss), net of tax, attributable to parent:(137)(140)(151)(66)250(37)(29)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: